The medication's acne-fighting benefits have been backed by science for decades, but it’s important to be aware of a few serious risks.

Rio Viera-Newton is an aesthetician and author of Let’s Face It: Secrets of a Skincare Obsessive. This column debuted in 2017.

Topline results were announced from a phase 3 trial evaluating Xyngari ™ (formerly DMT310) in patients with moderate to severe facial acne ... If the study produces positive results, the ...

If the STAR-2 study yields positive results, the Phase 3 program will support the ... s commitment to providing a novel treatment option for the over 30 million acne patients seeking treatment in the ...

Dermata's Xyngari showed significant acne improvement in Phase 3 results. A second pivotal trial is set for the second half of 2025.

Dermata said it plans to launch a second Phase 3 study in the second half of the year followed by an open-label extension study, adding that positive ... weekly topical acne product like Xyngari ...

Shares of Dermata Therapeutics (NASDAQ:DRMA) experienced a significant premarket surge, climbing 8.2% to $1.46, following the announcement of positive results from a late-stage clinical trial of its ...

Dermata Therapeutics (DRMA) announced positive topline results from the company’s first pivotal Phase 3 trial of xyngari, a novel, once-weekly, ...

But this felt ― and looked ― different. At first I thought it was one of those under-the-skin pimples that had led to a diagnosis of cystic acne and prescription of Lymecycline when I was 15, but the ...